Aims
The principal aim of CITR is to advance knowledge of cancer through research focused on the biological and translational relationship between malignant cells, immune responses, the tumor microenvironment, and therapeutic intervention.
The journal seeks contributions that provide robust evidence, meaningful scientific insight, methodological rigor, and appropriate interpretation.
Scope
Cancer Immunobiology
- CITR welcomes studies investigating:
- Tumor immune surveillance
- Immune recognition of malignant cells
- Antitumor immune responses
- Immune tolerance and suppression
- Tumor immune escape
- Innate and adaptive immunity
- Cancer-associated inflammation
- Tumor–immune signaling
- Antigen presentation
- Immune regulation during tumor progression
Tumor Microenvironment
- Research addressing the cellular and molecular characteristics of the tumor microenvironment, including:
- Tumor-infiltrating lymphocytes
- T-cell biology
- B-cell responses
- Natural killer cells
- Tumor-associated macrophages
- Myeloid-derived suppressor cells
- Cancer-associated fibroblasts
- Cytokines and chemokines
- Stromal–immune interactions
- Immune-metabolic regulation
Cancer Immunotherapy
- The journal considers research concerning:
- Immune checkpoint blockade
- Cellular immunotherapies
- CAR-T and related approaches
- T-cell receptor therapies
- Cancer vaccines
- Monoclonal antibodies
- Bispecific antibodies
- Cytokine-based interventions
- Immune agonists and modulators
- Combination immunotherapy
Translational Immuno-Oncology
- Research connecting biological findings with potential clinical applications, including:
- Biomarker discovery
- Predictive biomarkers
- Prognostic biomarkers
- Patient stratification
- Treatment-response assessment
- Companion diagnostics
- Translational models
- Immunotherapy monitoring
- Therapeutic-response prediction
Precision Cancer Immunology
- CITR encourages multidisciplinary approaches incorporating:
- Genomics
- Transcriptomics
- Proteomics
- Single-cell technologies
- Spatial profiling
- Multi-omics
- Computational immunology
- Systems biology
- Artificial intelligence and machine learning where scientifically appropriate
Immunotherapy Resistance
- Research investigating:
- Primary resistance
- Acquired resistance
- Immune escape
- Adaptive resistance
- Immune-excluded tumors
- Immune-desert phenotypes
- Mechanisms of treatment failure
- Strategies for overcoming resistance
Translational and Clinical Oncology
- The journal welcomes clinically relevant investigations involving:
- Immunotherapy outcomes
- Immune-related biomarkers
- Treatment response
- Patient stratification
- Cancer prognosis
- Translational clinical studies
- Real-world evidence
- Emerging therapeutic approaches